Search

Displaying results 5441 - 5450 of 6198 in total
  1. Drug

    AMP-201

    go.drugbank.com/drugs/DB18663
    Experimental

    AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.

  2. Drug

    Minzasolmin

    go.drugbank.com/drugs/DB18961
    Investigational

    Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's

  3. Drug

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide

    go.drugbank.com/drugs/DB02842
    Experimental

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.

  4. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  5. Drug

    Nemiralisib

    go.drugbank.com/drugs/DB16253
    Investigational

    Nemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary

  6. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  7. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This is a novel therapeutic approach to ...

  8. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties

  9. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.

  10. Drug

    Coronavirus-Like Particle COVID-19 Vaccine

    go.drugbank.com/drugs/DB15852
    Experimental

    The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. … In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known as [ISS-1018]), meant to provide an enhanced immune response to the vaccine.